Why the study?
While DANAMI-2 showed that interhospital transport to pPCI was superior to fibrinolysis at 30 days in STEMI patients, very long-term outcomes remained to be investigated.
Does primary percutaneous coronary intervention reduce the composite of death or rehospitalization for myocardial infarction in STEMI patients compared to fibrinolysis?
Does primary percutaneous coronary intervention reduce the composite of death or rehospitalization for myocardial infarction in STEMI patients compared to fibrinolysis?
Primary PCI provides a sustained long-term benefit over fibrinolysis in STEMI patients, reducing the composite of death or rehospitalization for MI and cardiac mortality at 16 years.
Answers are grounded in this paper and cite their sources.
Supports primary PCI over fibrinolysis for long-term STEMI outcomes; extends randomized evidence to 16-year follow-up.
AIMS: The DANish Acute Myocardial Infarction 2 (DANAMI-2) trial found that interhospital transport to primary percutaneous coronary intervention (pPCI) was superior to fibrinolysis at the local hospital in patients with ST-segment elevation myocardial infarction (STEMI) at 30 days. The present study investigates the 16-year cardiovascular outcomes. METHODS AND RESULTS: We randomized 1572 STEMI patients to pPCI or fibrinolysis at 24 referral hospitals and 5 invasive centres in Denmark. Patients randomized to pPCI at referral hospitals were immediately transported to the nearest invasive centre. The main endpoint of the current study was a composite of death or rehospitalization for myocardial infarction (MI). Outcome information beyond 3 years was obtained through Danish health registries. After 16 years, pPCI-treated patients had a sustained lower rate of composite endpoint compared to patients treated with fibrinolysis in the overall cohort [58.7% vs. 62.3%; hazard ratio (HR) 0.86, 95% confidence interval (CI) 0.76-0.98], and among patients transported for pPCI (58.7% vs. 64.1%; HR 0.82, 95% CI 0.71-0.96). No difference in all-cause mortality was found, but cardiac mortality was reduced by an absolute of 4.4% in favour of pPCI (18.3% vs. 22.7%; HR 0.78, 95% CI 0.63-0.98). pPCI postponed a main event with 12.3 months in average compared to fibrinolysis (95% CI 5.0-19.5). CONCLUSION: The benefit of pPCI over fibrinolysis was maintained at 16-year follow-up. pPCI reduced the composite endpoint of death or rehospitalization for MI, reduced cardiac mortality, and delayed average time to a main event by approximately 1 year.
No takes yet. Share an insight, caveat, or question.
Thrane et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: